Biotech company Biogen (NASDAQ:BIIB) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 2.9% ...

Biogen Inc. (NASDAQ:BIIB), currently valued at $19.15 billion by market capitalization, reported its earnings for the fourth quarter of 2024, surpassing analysts' expectations with a non-GAAP diluted ...

Wednesday closed down -0.27%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.50%, and the Nasdaq 100 Index ...

The decision means that Vumerity (diroximel fumarate) – a follow-up to Biogen's older oral therapy Tecfidera (dimethyl fumarate) – is now available to eligible patients across the UK ...

Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for slowing its progression. T ...

The S&P 500 Index ($SPX) (SPY) today is down -0.91%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.92%, and the ...

Biogen’s Skyclarys is on course to becoming ... which has recently also been cleared in the UK and US. The CHMP said the one-shot therapy has the potential to free patients from the burden ...

Also in today’s newsletter, Foxconn confirms interest in Nissan stake and Disney cuts diversity category from executive pay ...

EU Mid-Market Update: Another session with volatility weighted to second half of day as market waits for first US CPI reading ...

Biogen Inc is a biopharmaceutical company. It is engaged in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurological, rare and autoimmune diseases.

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...